Home › Funds › WESTFIELD CAPITAL MANAGEMENT CO LP › PCVX

WESTFIELD CAPITAL MANAGEMENT CO LP position in PCVX

VAXCYTE INC · Health Care

WESTFIELD CAPITAL MANAGEMENT CO LP reported holding 3,279,366 shares of PCVX (VAXCYTE INC) in its Q3 2026 13F filing — a position valued at US$186.6M, representing 0.61% of its reported portfolio and ranking #39 among its reported holdings. WESTFIELD CAPITAL MANAGEMENT CO LP has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.28M sh
Reported value held$186.60M
Portfolio Weight0.61%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How WESTFIELD CAPITAL MANAGEMENT CO LP's PCVX position evolved

WESTFIELD CAPITAL MANAGEMENT CO LP first disclosed a stake in PCVX in Q3 2023 at 1,003,916 shares (US$51.2M). The position peaked in Q1 2026 at 3,646,138 shares, worth US$211.9M. Across 13 filings, WESTFIELD CAPITAL MANAGEMENT CO LP increased the stake 8 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,279,366 shares valued at US$186.6M — an increase of 806,938 shares quarter over quarter.. Notable position changes include a 45% increase in Q4 2023 (shares rose 9% over the following quarter), a 48% increase in Q4 2024 (shares fell 54% over the following quarter), a 42% increase in Q2 2025 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.00M $51.18M New
Q4 2023 1.46M $91.41M Add
Q1 2024 1.59M $108.35M Add
Q2 2024 1.93M $145.69M Add
Q3 2024 1.74M $198.82M Reduce
Q4 2024 2.57M $210.11M Add
Q1 2025 2.16M $81.38M Reduce
Q2 2025 3.07M $99.77M Add
Q3 2025 3.73M $134.45M Add
Q4 2025 3.54M $163.32M Reduce
Q1 2026 3.65M $211.88M Add
Q2 2026 2.47M $143.72M Reduce
Q3 2026 3.28M $186.60M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 32 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has WESTFIELD CAPITAL MANAGEMENT CO LP held PCVX?

WESTFIELD CAPITAL MANAGEMENT CO LP has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is WESTFIELD CAPITAL MANAGEMENT CO LP's current position in PCVX?

As of Q3 2026, WESTFIELD CAPITAL MANAGEMENT CO LP holds 3.28M shares of PCVX (VAXCYTE INC), valued at $186.60M, representing 0.61% of its reported portfolio and ranking #39.

Has WESTFIELD CAPITAL MANAGEMENT CO LP been buying or selling PCVX?

In the latest 13F filing (Q3 2026), WESTFIELD CAPITAL MANAGEMENT CO LP increased its position in PCVX. The position peaked in Q1 2026 at 3.65M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.